Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction

Stroke is a rare but serious complication of acute myocardial infarction (AMI). Currently, glycoprotein (GP) IIb/IIIa inhibitor is used in clinical practice for acute coronary syndromes and percutaneous coronary interventions (PCIs). The incidence of stroke in patients receiving GP IIb/IIIa inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Woong Gil, Oh, Se Won, Kim, Young Joong, Lim, Jong Gu, Jo, Yoon Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193047/
https://www.ncbi.nlm.nih.gov/pubmed/22022331
http://dx.doi.org/10.4070/kcj.2011.41.9.546
Descripción
Sumario:Stroke is a rare but serious complication of acute myocardial infarction (AMI). Currently, glycoprotein (GP) IIb/IIIa inhibitor is used in clinical practice for acute coronary syndromes and percutaneous coronary interventions (PCIs). The incidence of stroke in patients receiving GP IIb/IIIa inhibitor during PCIs is very low. We report the case of a 47-year-old man who presented with AMI and suffered an acute cerebral infarction after infusion of a GP IIb/IIIa inhibitor following primary PCI.

Ejemplares similares